FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)

DUBLIN--(BUSINESS WIRE)--Dec. 13, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) voted...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials